Overview

Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer

Status:
Withdrawn
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical trial is to determine whether the combination of the established chemotherapeutic agent 5-fluorouracil(5-FU) and the large carbohydrate molecule GM-CT-01 is beneficial in treating advanced gall bladder and bile duct cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Galectin Therapeutics Inc.
Treatments:
Fluorouracil